Great Bay Bio (hence referred to as “GBB”) announced that its USD 15M Pre-series B fundraising, spearheaded by Tiger Jade Capital, has been completed (from now on referred to as “Tiger Jade”). One of the top life science MNCs in the world, AEF Greater Bay Area Fund (managed by Gobi Partners GBA), Vectr Ventures, and existing institutional investors all contributed to the funding’s oversubscription and upsizing.
The Hong Kong-based boutique investment bank DL Securities provided advice for the Pre-series B financing. Tiger Jade was founded by TigerMed, one of PRC’s biggest CROs for clinical trials. Its ecosystem includes over 300 businesses/clients, all of whom could directly or indirectly need the services of GBB.
GBB’s chairman and co-founder, Kingsley Leung, said:
“We are happy to hear that the market recognizes GBB’s game-changing innovations in the bioprocessing sector, and that investors value our strong forward-tested data and prospective commercial success. With the assistance of Tiger Jade Capital and a major multinational corporation, GBB will be able to integrate into the global biopharmaceutical ecosystem swiftly and realize its goal of Global Bioprocessing Made Simpler and More Efficient sooner. In turn, GBB will assist clients in shortening development cycles, lowering the price and risk of biomanufacturing, and ultimately enabling patients in need to access affordable biological medications.”
Their operations include more than 125 nations, serving as a foundation for future international business growth for GBB. The money raised will primarily be used to speed up the creation of platforms for bioprocessing powered by AI, building manufacturing facilities, and forming a global commercial development team. In the future, GBB will work to create and offer an “end-to-end” AI-enabled bioprocessing platform to meet international clients’ R&D and business needs.
Partner at Tiger Jade Capital, Mr. Jasper Jiang, said:
“We are pleased to include GBB, a superb domestically developed AI-driven bioprocessing startup in the Greater Bay Area of Guangdong, Hong Kong, and Macao, in our portfolio. The fact that GBB stands out in a competitive field and enjoys support from a prestigious global corporation and other reputable venture capital firms says a lot about the company’s technological advancements and future development potential. By making this investment, we think the Greater Bay Area will be more effectively developed following the national goal, and future capital entering the region’s biomedical industry will feel more secure.”
More about the startup:
Great Bay Bio (GBB), with its main office in Hong Kong, was established in 2019 and has a substantial presence in the Greater Bay Area. Following its corporate mission of “Global Bioprocessing Made Simpler and More Efficient,” GBB is dedicated to promoting bioprocessing innovations by utilizing AI and other cutting-edge technologies. This will help alleviate drug development problems, such as lengthy development cycles, high costs, and low success rates. GBB’s long-term objective is to improve human life, health, and value.
The core group of GBB comprises international experts in artificial intelligence, synthetic biology, medicine, and pharmacy. GBB has successfully advanced several biological pharmaceuticals through the NDA stage thanks to its 3000 m2 R&D center and CMC platform, including national class 1 novel medications.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
 announced that its USD 15M Pre-series B fundraising, spearheaded by Tiger Jade Capital, has been completed (from now on referred to as "Tiger Jade"). One of the top life science MNCs in the world, AEF Greater Bay Area Fund (managed by Gobi Partners GBA), Vectr Ventures, and existing institutional investors all contributed to the funding's oversubscription and upsizing.){kind=link}